Syndax Pharmaceuticals Inc
SNDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001395937
In the last 90 days, Syndax Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 242 institutions reported holding it in 13F filings for Q2 2026, worth $2.36B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Syndax Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $784.8K in total
- Insiders trading
- 1
- Net value
- −$784.8K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Syndax Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | 484,843 | Jul 9, 2026 | 4 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 60,885 | Jun 12, 2026 | 2 |
| Goldan Keith A. | Chief Financial Officer | 139,252 | Jun 2, 2026 | 4 |
| Podlesak Dennis | Director | 239,763 | Feb 6, 2026 | 1 |
| Katkin Keith | Director | 124,000 | Feb 6, 2026 | 1 |
| Legault Pierre | Director | 114,000 | Feb 6, 2026 | 1 |
| Huber Martin H. Jr. | Director | 103,000 | Feb 6, 2026 | 1 |
| Jarrett Jennifer | Director | 114,000 | Feb 6, 2026 | 1 |
| Rizo Aleksandra | Director | 49,000 | Feb 6, 2026 | 1 |
| Gallagher Neil | President, Head of R&D | 85,095 | Feb 12, 2025 | 0 |
| Meury William | Director | 90,000 | Feb 7, 2025 | 0 |
| Morrison Briggs | Director | 34,836 | Feb 9, 2024 | 0 |
| Ordentlich Peter | Chief Scientific Officer | 0 | Feb 17, 2023 | 0 |
| Nolte Alexander | Chief Accounting Officer | 0 | Feb 3, 2023 | 0 |
| Madigan Catherine | Chief Medical Officer | – | Feb 3, 2023 | 0 |
| Sabus Steve M | Chief Commercial Officer | – | Dec 5, 2022 | 0 |
| Egros Fabrice | Director | 32,000 | Feb 3, 2022 | 0 |
| Meyers Michael L. | SVP, Chief Medical Officer | 23,280 | Feb 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 18, 2025 (view filing) | Jul 16 | 2 days | Goldan Keith A.Chief Financial Officer | SSale | −1.30K | $9.29 | −$12.0K | −1.4%92.5K after | |
| Aug 18, 2025 (view filing) | Aug 14-18 | 4 days | Podlesak DennisDirector | SSale | −57.6K | $15.19 | −$874.9K | −23.1%191.8K after | 3 lots10b5-1 |
| Sep 8, 2025 (view filing) | Sep 8 | Same day | Metzger Michael AChief Executive Officer | SSale | −157.3K | $16.41 | −$2.58M | −34.5%298.7K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 6 | Same day | Goldan Keith A.Chief Financial Officer | SSale | −2.08K | $20.62 | −$42.9K | −1.4%143.8K after | |
| Feb 6, 2026 (view filing) | Feb 6 | Same day | Metzger Michael AChief Executive Officer | SSale | −7.41K | $20.62 | −$152.8K | −1.4%508.8K after | |
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | Goldan Keith A.Chief Financial Officer | SSale | −3.41K | $21.03 | −$71.7K | −2.4%140.4K after | |
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | Metzger Michael AChief Executive Officer | SSale | −17.2K | $21.03 | −$360.9K | −3.4%491.7K after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Metzger Michael AChief Executive Officer | SSale | −6.85K | $18.99 | −$130.0K | −1.4%484.8K after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Goldan Keith A.Chief Financial Officer | SSale | −1.18K | $18.99 | −$22.4K | −0.8%139.3K after | |
| Jun 12, 2026 (view filing) | Jun 11-12 | 1 day | Botwood Nicholas A.J.Head of R&D, CMO | SSale | −65.5K | $18.07 | −$1.18M | −51.8%60.9K after | 2 lots10b5-1 |
| Jul 9, 2026 (view filing)4:54 PM ET | Jul 8 | 1 day | Metzger Michael AChief Executive Officer | SSale | −32.4K | $24.24 | −$784.8K | −6.3%484.8K after | 10b5-1 |